Inc. reports roughly one in eight American adults is on a GLP-1 and looks at how that use is reshaping a major industry.
Recap by typeshit. Video by @inc on TikTok.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
A Facebook post says Lilly is pushing back on people selling its unapproved retatrutide, with few details beyond that.
In 2,749 adults with type 2 diabetes and high heart risk, Lilly's pill had fewer heart events and less low blood sugar, but GI side effects hit 62% of users.
Loading…